O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies

por Permanne, Bruno, Sand, Astrid, Ousson, Solenne, Nény, Maud, Hantson, Jennifer, Schubert, Ryan, Wiessner, Christoph, Quattropani, Anna, Beher, Dirk
Publicado 2022

Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies

por Hering, Heike, Graham, Danielle, Ousson, Solenne, Neny, Maud, Gray, Audrey, Giacomozzi, Brandy, Joyce, John, Dutt, Vikram, Busch, Michael, Cameron, Andrew, Liu-Bujalski, Leslie, Yu, Henry, Tian, Hui, Shearman, Mark, Quattropani, Anna, Permanne, Bruno, Wiessner, Christoph, Beher, Dirk
Publicado 2013